A family harboring a germ-line N-terminal C/EBPα mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPα mutation

Genes Chromosomes and Cancer

Volumn 49, Issue 3, 2010, Pages 237-241

  Nanri, Tomoko ^a   Uike, Naokuni ^b   Kawakita, Toshiro ^a   Iwanaga, Eisaku ^a   Mitsuya, Hiroaki ^a   Asou, Norio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN CEBPA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BASE PAIRING; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CODON; GENE INSERTION; GENE MUTATION; GERM LINE; HUMAN; KARYOTYPING; MALE; PRIORITY JOURNAL; SOMATIC MUTATION;

ADOLESCENT; ADULT; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; MUTATION; PEDIGREE; POLYMERASE CHAIN REACTION; SEQUENCE DELETION;

EID: 76649091256     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20734     Document Type: Article

References (27)

1. Asou N. 2003. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 45:129-150.
2. Asou N, Yanagida M, Huang L, Yamamoto M, Shigesada K, Mitsuya H, Ito Y, Osato M. 2007. Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. Blood 109:4023-4027.
3. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, Berna Beverloo H, Tenen DG, Lowenberg B, Delwel R. 2003. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4:31-40.
4. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K. 2004. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633.
5. Frohling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K. 2005. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer 42:427-432.
6. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, Larsen RJ, Asou H, Miller CW, Hoelzer D, Koeffler HP. 2002. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99:1332-1340.
7. Iwanaga E, Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N. 2009. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica 94:433-435.
8. Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, Kurz E, Theilgaard-Monch K, Mansson R, Pedersen TA, Pabst T, Schrock E, Porse BT, Jacobsen SE, Bertone P, Tenen DG, Nerlov C. 2008. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13:299-310.
9. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF. 2005. Characterization of CEBPA mutations in acute myeloid leukemia: Most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11:1372-1379.
10. Lin LI, Lin TC, Chou WC, Tang JL, Lin DT, Tien HF. 2006. A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia 20:1899-1903.
11. Matsuno N, Osato M, Yamashita N, Yanagida M, Nanri T, Fukushima T, Motoji T, Kusumoto S, Towatari M, Suzuki R, Naoe T, Nishii K, Shigesada K, Ohno R, Mitsuya H, Ito Y, Asou N. 2003. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. Leukemia 17:2492-2499.
12. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS. 2002. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 99:1364-1372.
13. Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N. 2005a. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia 19:1673-1675.
14. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, Asou N. 2005b. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 19:1361-1366.
15. Nerlov C. 2004. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer 4:394-400.
16. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y. 1999. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood 93:1817-1824.
17. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG. 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat Genet 27:263-270.
18. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. 2008. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26:5088-5093.
19. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H; ALFA Group. 2002. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723.
20. Renneville A, Mialou V, Philippe N, Kagialis-Girard S, Biggio V, Zabot MT, Thomas X, Bertrand Y, Preudhomme C. 2009. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23:804-806.
21. Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS. 2005. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19:1276-1278.
22. Shih LY, Liang DC, Huang CF, Wu JH, Lin TL, Wang PN, Dunn P, Kuo MC, Tang TC. 2006. AML patients with CEBPα mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: A comparative analysis on paired diagnosis and relapse samples. Leukemia 20:604-609.
23. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. 2004. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351:2403-2407.
24. Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ, Lister TA, Fitzgibbon J. 2003. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 37:72-78.
25. Tenen DG. 2003. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89-101.
26. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. 2009. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113:3088-3091.
27. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. 1997. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94:569-574.